Hair Growth Therapy (HARG/Minoxidil/LED)
Growth factor injection + oral + LED for hair density restoration
이 치료에 대해
HARG therapy injects growth factors (AAPE from adipose stem cells) directly into the scalp. Combined with finasteride/dutasteride oral therapy, topical minoxidil, and low-level laser therapy (LLLT) for comprehensive hair loss treatment.
Addresses both male (AGA) and female pattern hair loss (FPHL) by activating follicular stem cells and inducing anagen.
작용 기전
AAPE growth factors (KGF, PDGF, VEGF, HGF) activate Wnt/β-catenin signaling in follicular stem cells, transitioning telogen follicles to anagen. Finasteride inhibits 5α-reductase type II (reduces DHT). Dutasteride blocks types I and II. Minoxidil causes vasodilation via KATP channels plus direct follicular stimulation. LLLT activates mitochondrial cytochrome C oxidase for increased ATP.
적응증
기대 효과
HARG: 70-80% of patients show density improvement after 6 sessions (monthly). Finasteride: AGA stabilization + regrowth at 6-12 months. Minoxidil: effects at 4-6 months. LLLT: density increase at 16-26 weeks. Combined program for maximum results.
임상 근거
위험 및 부작용
HARG: scalp pain/redness (same day). Finasteride: sexual dysfunction (1-2%), contraindicated in women/pregnant. Dutasteride: similar side effects slightly higher. Topical minoxidil: scalp itching/flaking. LLLT: virtually no side effects.